Evidence map›Paper›PMID 39194089›Full record

ArticleCadernos de saude publica2024

Cohort profile: follow-up of a household cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil.

Michele Fernanda Borges da Silva, Lusiele Guaraldo, Heloisa Ferreira Pinto Santos, Leonardo Soares Bastos, Anielle de Pina-Costa, Stephanie Lema Suarez Penetra, Isabella Campos Vargas de Moraes, Guilherme Amaral Calvet, Trevon Louis Fuller, Paola Cristina Resende Silva and 2 more

Abstract read
In one paragraph

Article in Cadernos de saude publica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michele Fernanda Borges da SilvaInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0001-5710-4124
Lusiele GuaraldoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0003-0047-6538
Heloisa Ferreira Pinto SantosInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0002-6353-9172
Leonardo Soares BastosPrograma de Computação Científica, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0002-1406-0122
Anielle de Pina-CostaInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0002-5527-2295
Stephanie Lema Suarez PenetraInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0002-0943-8776
Isabella Campos Vargas de MoraesInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0002-7797-6971
Guilherme Amaral CalvetInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0002-3545-5238
Trevon Louis FullerUniversity of California, Los Angeles, U.S.A.ORCID 0000-0001-9954-4267
Paola Cristina Resende SilvaInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0002-2884-3662
Marilda Agudo Mendonça Teixeira de SiqueiraInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0003-4685-9817
Patricia BrasilInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.ORCID 0000-0001-9555-7976

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since May 2020, we have been conducting a comprehensive study to understand the natural history of SARS-CoV-2 infection in Rio de Janeiro, Brazil. Our focus has been on following families, systematically collecting respiratory tract swabs and blood samples, monitoring symptoms, and gathering data on vaccine status. This paper aims to describe the household cohort across five epidemic waves of SARS-CoV-2, providing an overview of the collected data and a description of the epidemiological, clinical, and immunological characteristics and incidence of SARS-CoV-2 infection. Our cohort includes 691 participants from 189 households. During the five epidemic waves, we detected 606 infections. The incidence density of SARS-CoV-2 infection ranged from 4 (Delta) to 56 (B.1.1.33) per 1,000 person-week, with a peak in wave B.1.1.33 in all age groups. The seroprevalence of SARS-CoV-2 antibodies (IgG anti spike protein) varied from 37%, in the pre-VoC period, to 99%, in the Omicron period, progressively increasing after each wave in a similar manner regardless of age. As we have monitored the cohort continuously since the beginning of the pandemic, we were able to collect data across different scenarios according to the predominant lineage in circulation. Via active monitoring of families, we were able to carry out an epidemiological surveillance on SARS-CoV-2, including its variants, persistence of symptoms, and changes in immunity over time in the population, contributing to knowledge of the natural history of SARS-CoV-2 infection.

Indexed as

COVID-19Family CharacteristicsSARS-CoV-2AdolescentAdultAgedAntibodies, ViralBrazilChildChild, PreschoolCohort StudiesFemaleFollow-Up StudiesHumansIncidenceInfantAntibodies, Viral

Identifiers

PMID39194089
PMCPMC11349275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.